Grazia Caivano

Dr. Grazia Caivano


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
FOFiona O'Brien
Fiona O'Brien
DCDavid Clapham
David Clapham
KKKamelia Krysiak
Kamelia Krysiak
HBHannah Batchelor
Hannah Batchelor
PFPeter Field
Peter Field
Catherine TuleuCatherine Tuleu
Catherine Tuleu
The development of age-appropriate formulations should focus on dosage forms that can deliver variable yet accurate doses that are safe and acceptable to the child, are matched to his/her development and ability, and avoid medication errors. However, in the past decade, the medication needs of neonates have largely been neglected. The aim of this review is to expand on what differentiates the needs of preterm and term neonates from those of the older paediatric subsets, in terms of environment of care, ability to measure and administer the dose (from the perspective of the patient and carer, the routes of administration, the device and the product), neonatal biopharmaceutics and regulatory challenges. This review offers insight into those challenges posed by the formulation of medicinal products for neonatal patients in order to support the development of clinically relevant products.

17 August 2024 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
SSSmita Salunke
Smita Salunke
AAAnjali Agrawal
Anjali Agrawal
JWJennifer Walsh
Jennifer Walsh
ANAnthony Nunn
Anthony Nunn
KHKevin Hughes
Kevin Hughes
PSPhilip Sherratt
Philip Sherratt

Verified
Journal Article
Open access
PDF file
CSCarsten Schwarz
Carsten Schwarz
CPClaudio Procaccianti
Claudio Procaccianti
LCLaura Costa
Laura Costa
RBRiccardo Brini
Riccardo Brini
RFRichard Friend
Richard Friend
FBFederico Bianco
Federico Bianco
We compared the performance and levofloxacin (Quinsair) lung deposition of three nebulisers commonly used in CF (I-Neb Advance, eFlow rapid, and LC Plus) with the approved nebuliser Zirela. The delivered dose, delivery rate, and aerosol particle size distribution (APSD) for each device were determined using the methods described in the Pharmacopeia. High-resolution computed tomography scans obtained from seven adult patients with mild CF were used to generate computer-aided, three-dimensional models of their airway tree to assess lung deposition using functional respiratory imaging (FRI). The eFlow rapid and the LC Plus showed poor delivery efficiencies due to their high residual volumes. The I-Neb, which only delivers aerosols during the inspiratory phase, achieved the highest aerosol delivery efficiency. However, the I-Neb showed the largest particle size and lowest delivery rate (2.9 mg/min), which were respectively associated with a high extrathoracic deposition and extremely long nebulisation times (>20 min). Zirela showed the best performance considering delivery efficiency (159.6 mg out of a nominal dose of 240 mg), delivery rate (43.5 mg/min), and lung deposition (20% of the nominal dose), requiring less than 5 min to deliver a full dose of levofloxacin. The present study supports the use of drug-specific nebulisers and discourages the off-label use of general-purpose devices with the present levofloxacin formulation since subtherapeutic lung doses and long nebulisation times may compromise treatment efficacy and adherence.

8 August 2024 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Open access
AAAnjali Agrawal
Anjali Agrawal
SSSmita Salunke
Smita Salunke
ARAlfred Rumondor
Alfred Rumondor
KTKaren Thompson
Karen Thompson
GCGrazia Caivano
Grazia Caivano
PKPeter Kuehl
Peter Kuehl
It is necessary to use a scientifically sound process for excipient risk evaluation, selection, and management in order to develop paediatric medicinal products that are both safe and effective. The "Paediatric Excipient Risk Assessment (PERA)" framework, which proposes a comprehensive approach by considering all relevant factors related to patient, dosage form, and excipient attributes, was developed and published as part 1 of this paper series, to enable the rational selection of excipients for paediatric medicinal products. This article is Part 2 of the series and presents the PERA tool that allows easy adoption of the PERA framework. Using a straightforward heat map scoring approach (Red, Yellow, and Green category) for risk evaluation, the PERA tool can be used to compare and choose excipients. The PERA tool will help users identify potential gaps in excipients information that will help with risk-based mitigation planning. Several case studies covering frequently used and novel excipients for oral, as well as the choice of excipient for parenteral products for neonatal administration, serve to illustrate the PERA tool's usefulness.